ライブ
Clinical OMICsBlood-Based Risk Score Could Enable Earlier Lung Cancer PreventionClinical OMICsMicroglial State Shift May Determine Whether Alzheimer’s Disease Pathology Leads to DementiaEndpoints NewsIn Washington, biotech's China hawks are winning the conversationClinical OMICsUniversal Coronavirus Vaccine Could Provide Protection Against Future StrainsEndpoints NewsIndustry seeks more clarity on commissioner's voucher programBioWorldMoney raised by biopharmaBioWorldBiopharma money raised: Jan. 1-June 4, 2026BioWorldBioWorld and Nasdaq stock indicesEndpoints NewsHouse committee directs FDA to speed up IND sign-off processFierceBiotechExecutive Interviews at Fierce Biotech Week 2026BioWorldBiopharma money raised by month in 2026 (US$M)BioPharma DiveStudy data convince Lundbeck to push new migraine drug forward
Agilent 2026年2月27日

Goldman Sachs Adjusts Price Target on Agilent Technologies to $150 From $170, Maintains Buy Rating - marketscreener.com

Goldman Sachs Adjusts Price Target on Agilent Technologies to $150 From $170, Maintains Buy Rating - marketscreener.com

原文
本文は利用できません。元の情報源をご確認ください。